European approval leverage NTTS holds European approval for recurrent glioblastoma, indicating a validated platform with regulatory credibility that can be leveraged to engage European cancer centers and regional distributors seeking approved nanotech therapies.

Niche oncology focus The company targets glioblastoma with a nanotechnology-based therapy, presenting a differentiated value proposition for neuro-oncology departments and hospitals seeking innovative, minimally invasive treatments with potential quality of life benefits.

Small team agility With a lean headcount, MagForce can be a fast-moving partner for pilot programs, clinical collaborations, or joint development initiatives, offering flexibility in deal structuring and rapid decision cycles.

Early-stage funding signals Current revenue is modest while funding stands at a few million, suggesting room for growth through strategic partnerships, licensing, or co-development deals with larger medical device or biotech players.

Global expansion potential Having an international ambition to reach patients worldwide, there is opportunity to explore distribution agreements, regional commercialization rights, and hospital adoption programs across Europe and other continents.